About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
FGEN - FibroGen| Previous Close | $42.79 | Open | $42.61 |
| Volume | 769K | Market Cap | 3.866B |
| Yield | Last Dividend |
| The Daily Biotech Pulse: AbbVie In-licen... | 09/04/20 |
| Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3) Akouos Inc (NASDAQ: AKUS ) FibroGen Inc (NASDAQ: FGEN )(reacted to an adverse clinica... | |
| Thinking about trading options or stock ... | 09/03/20 |
| NEW YORK , Sept. 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FGEN, BYND, LLY, BAC, and TSLA. Click a link below th... | |
| FibroGen Reports Second Quarter 2020 Fin... | 08/06/20 |
| - Strong Second Quarter China Roxadustat Net Sales of $15.7 million -- Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time - SAN??? | |
| PSEi inches up on bargain hunting | 07/10/20 |
| The local stock barometer ended marginally higher on Friday after falling most days of the week due to concerns on rising coronavirus infections local... | |
| KKR acquires stake in Philippine power p... | 06/29/20 |
| KKR (NYSE:KKR) will acquire an ~11.9% stake in Philippine power producer First Gen Corporation (OTCPK:FSGCY) through its tender offer for the shares. ... | |
| FibroGen Initiates Phase II/III Study in... | 06/09/20 |
| FibroGen (FGEN) starts a phase II/III study in Italy on pamrevlumab versus standard of care in patients with severe COVID-19 infection. | |
| European Medicines Agency Accepts Astell... | 05/20/20 |
| TOKYO and SAN FRANCISCO , May 20, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and Fib... | |
| Why FibroGen (FGEN) Might Surprise This ... | 05/06/20 |
| FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. | |
| FibroGen (FGEN) Expected to Beat Earning... | 04/30/20 |
| FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the ke... | |
| The Daily Biotech Pulse: Mylan Ramps Up ... | 03/20/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) ... | |
| The Daily Biotech Pulse: Pfizer's Eczema... | 03/19/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18)... | |
| FibroGen EPS misses by $0.54, misses on ... | 03/02/20 |
| FibroGen (NASDAQ:FGEN): Q4 GAAP EPS of -$1.12 misses by $0.54. Revenue of $7.97M (-92.6% Y/Y) misses by $32.35M. Cash and cash equivalents of $533.76M... | |
| The Daily Biotech Pulse: Sanofi Reports ... | 01/30/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 29) ... | |
| Astellas Submits Supplemental New Drug A... | 01/30/20 |
| TOKYO and SAN FRANCISCO, Jan. 30, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Fibr... | |
| FIBROGEN ALERT: Bragar Eagel & Squire, P... | 11/14/19 |
| NEW YORK--(BUSINESS WIRE)-- #fibrogen--Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims ag... | |
| Glancy Prongay & Murray LLP Announces In... | 11/13/19 |
| LOS ANGELES--(BUSINESS WIRE)---- $FGEN--Glancy Prongay & Murray LLP Announces Investigation on Behalf of FibroGen, Inc. Investors | |
| FibroGen, AstraZeneca Up After Roxadusta... | 11/08/19 |
| By Michael Dabaie AstraZeneca and FibroGen said roxadustat Phase III program pooled analyses showed positive efficacy and no increased cardiovascular ... | |
| Zacks.com featured highlights include: B... | 10/17/19 |
| Zacks.com featured highlights include: B2Gold, Burlington Stores, FibroGen, Matrix Service Company and Great Lakes Dredge & Dock | |
| FibroGen Enters Oversold Territory | 10/03/19 |
| FibroGen, Inc. (FGEN) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. | |
| FibroGen Begins Study on Roxadustat for ... | 09/27/19 |
| FibroGen (FGEN) doses the first patient in a phase II study on roxadustat for the treatment of anemia in cancer patients receiving chemotherapy. | |
| FibroGen's Evrenzo Gets Nod in Japan for... | 09/20/19 |
| FibroGen's (FGEN) Evrenzo (roxadustat) wins a marketing approval in Japan for treating anemia caused by chronic kidney disease in dialysis-dependent p... | |
| Zacks.com featured highlights include: A... | 09/13/19 |
| Zacks.com featured highlights include: ACM, FibroGen, Funko, Matrix Service and PetIQ | |
| FibroGen (FGEN) Catches Eye: Stock Jumps... | 08/27/19 |
| FibroGen (FGEN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes. | |
| The Daily Biotech Pulse: ViiV's Long-Act... | 08/22/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 21) ... | |
| FibroGen (FGEN) Q2 Earnings and Revenues... | 08/08/19 |
| FibroGen (FGEN) delivered earnings and revenue surprises of 357.14% and 492.72%, respectively, for the quarter ended June 2019. Do the numbers hold cl... | |
| Earnings Preview: FibroGen (FGEN) Q2 Ear... | 07/30/19 |
| FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with ... | |
| FibroGen's Roxadustat Shows A Clear Posi... | 05/22/19 |
| No summary available. | |
| Implied Volatility Surging for FibroGen ... | 05/16/19 |
| Investors need to pay close attention to FibroGen (FGEN) stock based on the movements in the options market lately. | |
| FibroGen Inc (FGEN) Q1 2019 Earnings Cal... | 05/13/19 |
| FGEN earnings call for the period ending March 31, 2019. | |
| Here's Why FibroGen Fell as Much as 26.6... | 05/10/19 |
| The company reported confusing top-line results from an important batch of phase 3 safety studies. Were they successful? | |
| Strong Buy rating | 09/08/20 |
| SVB Leerink initiates coverage with Outperform rating and raises Price Target from $84.00 to $90.00 | |
| Strong Buy rating | 08/07/20 |
| SVB Leerink maintains Outperform rating and raises Price Target from $80.00 to $84.00 | |
| Date | 2020-08-06 (AMC) | Est. (EPS/Rev.) | ($0.50)/ 49.73M |
| Actual (EPS/Rev.) | $-0.95/ $42.89 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Biotechnology | Robert Gadimian | 26.00 % | Follow |
| cerevisiology | John Cho | 19.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
